Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 0.62 |
| ▸ | MTNR1B | P49286 | 9/20 | 0.62 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 10/20 | 0.40 |
| ▸ | HTR2A | P28223 | 8/20 | 0.40 |
| ▸ | HTR2B | P41595 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12394492 | 1.00 | MTNR1A (0.62) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL340076 | 1.00 | MTNR1A (0.62) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL11917773 | 1.00 | MTNR1A (0.62) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| Hydrochloric Acid SCHEMBL339856 | 0.99 | MTNR1A (0.60) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| Hydrochloric Acid SCHEMBL339855 | 0.99 | MTNR1A (0.60) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| Hydrochloric Acid SCHEMBL29794521 | 0.99 | MTNR1A (0.60) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| Bromide SCHEMBL2879815 | 0.99 | MTNR1A (0.60) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL28361707 | 0.85 | MTNR1A (0.65) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL28357968 | 0.85 | MTNR1A (0.65) | MTNR1AMTNR1BABCB11SIGMAR1USP2 | |
| SCHEMBL12056685 | 0.85 | MTNR1A (0.67) | MTNR1AMTNR1BABCB11SIGMAR1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111170970-A | Preparation method of ramelteon | 北京万全德众医药生物技术有限公司 | 2020-05-19 | — | — | CN | claimed |
| EP-1792899-B1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2014-07-09 | — | — | EP | claimed |
| US-20140066499-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-03-06 | — | — | US | claimed |
| US-8097737-B2 | Process for production of optically active amine derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-17 | — | — | US | claimed |
| US-20110207949-A1 | PROCESS FOR THE PREPARATION OF RAMELTEON | Watson Pharma Private Limited (IN) | 2011-08-25 | — | — | US | claimed |
| EP-2344468-A1 | PROCESS FOR THE PREPARATION OF RAMELTEON | Watson Pharma Private Limited (IN) | 2011-07-20 | — | — | EP | claimed |
| WO-2011027323-A1 | PROCESS FOR THE PREPARATION OF RAMELTEON | RANBAXY LABORATORIES LIMITED (IN) | 2011-03-10 | — | — | WO | claimed |
| WO-2011027319-A1 | PROCESS FOR THE PREPARATION OF AN INTERMEDIATE FOR RAMELTEON | RANBAXY LABORATORIES LIMITED (IN) | 2011-03-10 | — | — | WO | claimed |
| WO-2010055481-A1 | PROCESS FOR THE PREPARATION OF RAMELTEON | Watson Pharma Private Limited (IN) | 2010-05-20 | — | — | WO | claimed |
| WO-2010041271-A2 | PROCESS FOR PREPARATION OF (S)-N-[2-(1,6,7,8-TETRAHYDRO-2H-INDENO[5,4-B]FURAN-8-YL)ETHYL] PROPIONAMIDE AND NOVEL INTERMEDIATES THEREOF | USV LIMITED (IN) | 2010-04-15 | — | — | WO | claimed |
| US-20090036521-A1 | Process for Production of Optically Active Amine Derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-05 | — | — | US | claimed |
| EP-1792899-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2007-06-06 | — | — | EP | claimed |
| WO-2021210920-A1 | METHOD FOR PRODUCING RAMELTEON, AND INTERMEDIATE COMPOUND USED FOR SAME | 제이투에이치바이오텍 주식회사 | 2021-10-21 | — | — | WO | disclosed |
| WO-2021210920-A1 | METHOD FOR PRODUCING RAMELTEON, AND INTERMEDIATE COMPOUND USED FOR SAME | 제이투에이치바이오텍 주식회사 | 2021-10-21 | — | — | WO | disclosed |
| CN-111170970-A | Preparation method of ramelteon | 北京万全德众医药生物技术有限公司 | 2020-05-19 | — | — | CN | disclosed |
| CN-104119307-A | Preparation method for (S)-2-(1,6,7,8-tetrahydro-2H-indeno[5,4-B]furan-8-yl)ethylamine | CISEN PHARMACEUTICAL CO LTD | 2014-10-29 | — | — | CN | disclosed |
| US-6034239-A | BINDIG TO MELATONIN RECEPTORS; SLEEP DISORDERS; GLANDULAR DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-03-07 | — | — | US | disclosed |
| WO-1999063977-A2 | PHARMACEUTICAL COMBINATION COMPRISING A TRICYCLIC COMPOUND AND AT LEAST ONE OF ZOLPIDEM, ZOPICLONE, TRIAZOLAM AND BROTIZOLAM FOR TREATING OR PREVENTING SLEEP DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-12-16 | — | — | WO | disclosed |
| EP-0885210-A1 | Tricylic compounds having binding affinity for melatonin receptors, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997032871-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066499-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINE DERIVATIVES | INMT, TYR, PNMT | MTNR1A 3077/4885MTNR1B 2236/4885ABCB11 3751/4885 |
| US-20110207949-A1 | PROCESS FOR THE PREPARATION OF RAMELTEON | CYP2B6, CYP2A6, UGT1A6 | MTNR1A 190/4885MTNR1B 111/4885ABCB11 1856/4885 |
| US-20090036521-A1 | Process for Production of Optically Active Amine Derivatives | INMT, TYR, PNMT | MTNR1A 3077/4885MTNR1B 2236/4885ABCB11 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.